Receive monthly emails about the latest oncology research and technology, new patient services, resources and more!

Please select an option below to help us tailor your newsletter to best suit your content interests!

No thanks
West Cancer Center
Stage
Phase
Status
Reset Filter
CLL/SLL: Previously treated: on BTK monotherapy: GLORA

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

VIEW TRIAL ON CLINICALTRIALS.GOV
Malignancy

Chronic lymphocytic leukemia, small lymphocytic lymphoma, CLL, SLL

Stage

Stage 4

Phase

Phase 3

Status

Open to Enrollment

Line Of Therapy

Previously treated

Investigational Agent

Lisaftoclax

Drug Class

BCL-2 inhibitor

PI

Jason Chandler, MD

Sponsor

Ascentage Pharma Group, Inc

Path

CLL, SLL

Key Eligibility Criteria Details
  • Age ≥ 18 years.
  • .Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
  • ECOG Performance Status grade 0-2

  • Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows

  • Adequate renal function

  • Adequate liver function

X